lundi 8 avril 2019

Onco Actu du 8 avril 2019


1.1 BIOLOGIE - GÈNES



Cancer geneticists tackle troubling ethnic bias in studies [Nature]










5.1 TRAITEMENTS - PRÉ-CLINIQUE



Using a promiscuous inhibitor to uncover cancer drug targets [EurekAlert!]











5.12 IMMUNOTHÉRAPIES



What causes immuno-oncology drug resistance? 2 research teams uncover clues [Fierce Biotech]











5.12.8 IMMUNOTHÉRAPIES - ECONOMIE



Kidney cancer immunotherapy combo approved for NHS use in England [Cancer Research UK]











5.2 PHARMA



No return for the Merrimack [Biopharma Dive]











The point of no return for Merrimack? Cancer drug developer axes yet another drug and more staff [EndPoints]











5.2.3 PHARMA - ÉCONOMIE



The top 15 pharma companies by 2018 revenue [Fierce Pharma]











5.3 TRAITEMENTS - FDA, EMA, NICE...



FDA declares 40 generics free of carcinogens as 'sartan' recalls continue [Fierce Pharma]











5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)



Pfizer uses real-world data to score Ibrance breast cancer nod in males [Fierce Pharma]











Pfizer wins expanded Ibrance approval using real world data [Biopharma Dive]











5.4 TRAITEMENTS - ECONOMIE



Prostate cancer hormone therapy rejected on NHS in England [Cancer Research UK]










6. LUTTE CONTRE LES CANCERS



Chemotherapy doses review after 14 NHS Tayside patients die [BBC News]











6.10 POLITIQUES



Labor’s cancer package would cut the cost of care, but beware of unintended side effect [The Conversation]











Labor’s Cancer Package – short and longer term implications for the health system [Croakey]











6.11 PATIENTS



Game of Thrones, cancer and me… [The Guardian]











6.12 ETHIQUE



Outside review confirms top Memorial Sloan Kettering executives flouted conflicts-of-interest policies — report [EndPoints]











6.2 IMPLANTS MAMMAIRES



France Is First to Ban Breast Implants Linked to Rare Cancer [NY Times]










6.4 MÉDICO-ÉCO



Study calculates costs associated with smoking by patients with cancer [MUSC]










Attributable Failure of First-line Cancer Treatment and Incremental Costs Associated With Smoking by Patients With Cancer [JAMA Network Open]











6.6 PUBLICATIONS



Fining one ‘predatory’ publisher won’t fix the problem of bad science in journals [STAT]